

**Investor Contact:**

Robert G. Burrows  
Vice President, Investor Relations  
240-631-3280  
BurrowsR@ebsi.com

**Media Contact:**

Tracey Schmitt Lintott  
Vice President, Global Public Affairs  
and Corporate Responsibility  
240-631-3394  
SchmittT@ebsi.com

**EMERGENT BIOSOLUTIONS TO PARTICIPATE IN FIRST QUARTER 2016 INVESTOR CONFERENCES**

**GAITHERSBURG, MD, December 21, 2015**—Emergent BioSolutions Inc. (NYSE: EBS) announced today that a member of the company's senior management team will participate in the following investor conferences during the first quarter of 2016.

- **34<sup>th</sup> Annual J.P. Morgan Healthcare Conference**  
San Francisco, CA  
January 11-14, 2016  
Presentation: January 11, 2016 - 2:00PM Eastern
- **Wells Fargo Specialty and Generic Drug Summit**  
February 22, 2016  
New York, NY  
Presentation time TBD
- **RBC Healthcare Conference**  
February 23-24, 2016  
New York, NY  
Presentation day and time TBD
- **Cowen & Co. Annual Health Care Conference**  
March 7-9, 2016  
Boston, MA  
Presentation day and time TBD

Presentation dates and times will be updated on the Emergent website [www.emergentbiosolutions.com](http://www.emergentbiosolutions.com) under "Investors" as this information becomes available.

For these conferences, the company will be webcasting its presentation, which may include a discussion of the company's recent business developments as well as its most recently reported financial results and guidance. The webcasts will be available both live and by replay, accessible from the Emergent website.

**About Emergent BioSolutions Inc.**

Emergent BioSolutions is a global specialty biopharmaceutical company dedicated to one simple mission—to protect and enhance life. We develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. We also develop and commercialize therapeutics and other specialty products for hospitals and clinics in the areas of hematology/oncology, transplantation, infectious diseases and autoimmune disorders. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025. Additional information about the company may be found at [www.emergentbiosolutions.com](http://www.emergentbiosolutions.com).

Follow us on twitter: [@emergentbiosolu](https://twitter.com/emergentbiosolu).

###